| Population 2015 |
25 million |
| |
| | | | | |
| Estimates of TB burden*, 2015 |
Number (thousands) |
Rate
(per 100 000 population) |
| Mortality (excludes HIV+TB) |
11 |
(6.6–17) |
45 |
(27–67) |
| Mortality (HIV+TB only) |
7.2 |
(1.6–17) |
29 |
(6.5–67) |
| Incidence (includes HIV+TB) |
93 |
(60–132) |
370 |
(240–529) |
| Incidence (HIV+TB only) |
28 |
(17–41) |
111 |
(68–165) |
| Incidence (MDR/RR-TB)** |
4.1 |
(0.36–7.8) |
16 |
(1.4–31) |
| |
| | | | | |
| Estimated TB incidence by age and sex (thousands)*, 2015 |
| |
0-14 years |
> 14 years |
Total |
| Females |
5.7 |
(3.1–8.4) |
34 |
(16–51) |
40 |
(19–60) |
| Males |
4.4 |
(2.6–6.2) |
49 |
(34–64) |
53 |
(36–70) |
| Total |
10 |
(6.6–14) |
83 |
(63–102) |
93 |
(60–132) |
| |
| | | | | |
| TB case notifications, 2015 |
|
| Total cases notified |
61 060 |
| Total new and relapse |
59 705 |
| - % tested with rapid diagnostics at time of diagnosis |
|
| - % with known HIV status |
23% |
| - % pulmonary |
93% |
| - % bacteriologically confirmed among pulmonary |
51% |
| |
| | | | | |
| Universal health coverage and social protection |
|
| TB treatment coverage (notified/estimated incidence), 2015 |
64% (45–100) |
| TB patients facing catastrophic total costs |
|
| TB case fatality ratio (estimated mortality/estimated incidence), 2015 |
0.21 (0.1–0.37) |
| |
| | | | | |
| TB/HIV care in new and relapse TB patients, 2015 |
Number |
(%) |
| Patients with known HIV-status who are HIV-positive |
1 558 |
12% |
| - on antiretroviral therapy |
|
|
| |
| | | | | |
| Drug-resistant TB care, 2015 |
New cases |
Previously treated
cases |
Total
number*** |
Estimated MDR/RR-TB cases among notified
pulmonary TB cases |
|
2 700
(430–5 000) |
| Estimated % of TB cases with MDR/RR-TB |
2.8% (0.1–6.7) |
21% (2.2–39) |
|
| % notified tested for rifampicin resistance |
|
|
227 |
| MDR/RR-TB cases tested for resistance to second-line drugs |
|
0 |
| Laboratory-confirmed cases |
MDR/RR-TB: 227, XDR-TB: 0 |
| Patients started on treatment **** |
MDR/RR-TB: 227, XDR-TB: 0 |
| |
| | | | | |
| Treatment success rate and cohort size |
Success |
Cohort |
| New and relapse cases registered in 2014 |
34% |
53 552 |
| Previously treated cases, excluding relapse, registered in 2014 |
66% |
1 654 |
| HIV-positive TB cases, all types, registered in 2014 |
|
|
| MDR/RR-TB cases started on second-line treatment in 2013 |
74% |
116 |
| XDR-TB cases started on second-line treatment in 2013 |
|
|
| |
| | | | | |
| TB preventive treatment, 2015 |
|
| % of HIV-positive people (newly enrolled in care) on preventive treatment |
|
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment |
|
| |
| | | | | |
| TB financing, 2016 |
|
| National TB budget (US$ millions) |
22 |
| Funding source: 39% domestic, 0% international, 61% unfunded |
| |
| | | | | |
| * Ranges represent uncertainty intervals | | | | | |
| ** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin | | | |
| *** Includes cases with unknown previous TB treatment history | | | | |
| **** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed | | |
| | | | | |